Noom is expanding beyond GLP-1 weight loss drugs and positioning itself in the growing peptide market, acquiring a compounding pharmacy to support this shift. As regulatory pressure increases on GLP-1 compounding, digital health companies are looking to peptides as the next opportunity tied to preventive health and longevity. However, many of these products remain restricted by the FDA due to safety concerns and limited clinical evidence, leaving companies navigating a rapidly evolving and uncertain regulatory landscape.
In a feature by Endpoints News, Edgar Asebey highlights that the legality of many peptides is not a gray area—most are unapproved for human use and cannot be lawfully compounded. He notes that companies offering these products face real enforcement risk, including FDA warning letters and potential penalties. Asebey also points to the surge in demand driven by online markets and wellness trends, underscoring the need for companies to prioritize compliance as regulators continue to scrutinize this space.
Read the full article with Endpoints News.
